Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00997152 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients
A Phase 2 study, sponsored by Akros Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 152
- Enrollment target
NCT00997152 is a Phase 2 study that was terminated before completion, run by Akros Pharma. The registered enrollment target is 152 participants.
The verdict
NCT00997152, a Phase 2 study, was terminated before completion, sponsored by Akros Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 152 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of JTT-654 on diabetes as well as the safety, tolerability and pharmacokinetics of JTT-654 in type 2 diabetic patients.
Interventions
- DRUG JTT-654
- DRUG JTT-654 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2009-09 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00997152
The ClinicalTrials.gov registry entry for NCT00997152 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akros Pharma, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which JTT-654 is the first listed.
NCT00997152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00997152 about?
NCT00997152 is a clinical study titled "Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients". The purpose of this study is to evaluate the effect of JTT-654 on diabetes as well as the safety, tolerability and pharmacokinetics of JTT-654 in type 2 diabetic patients.
What is the current status of trial NCT00997152?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 152 participants. The study started on 2009-09. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00997152?
The interventions under investigation include: JTT-654 (DRUG), JTT-654 Placebo (DRUG).
Who is sponsoring clinical trial NCT00997152?
This trial is sponsored by Akros Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.